Home Featured Page 262

Featured

Latest

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

PT238 – Kile Ortigo – Integration and Existential Exploration

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Psychedelic Bulletin: UCSF Launches Psychedelics Division; New Additions to the Psychedelics...

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

1...261262263...296 Page 262 of 296

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

PT238 – Kile Ortigo – Integration and Existential Exploration

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Psychedelic Bulletin: UCSF Launches Psychedelics Division; New Additions to the Psychedelics...

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY